

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	17/NW/0022	219189	Post-Authorization Study of HyQvia in Pediatric PIDD subjects	Number Agreed	2	2	Date Agreed	31/12/2019	5	22/10/2019	5	Recruitment Finished
2	17/YH/0392	230501	BI 1467335 in patients with diabetic retinopathy.	Number Agreed	2	2	Date Agreed	31/10/2019	2	31/10/2019	2	Recruitment Finished
3	19/EM/0047	257111	GR40306 (TENAYA): A study of faricimab in nAMD	Number Agreed	4	4	Date Agreed	31/12/2019	4	31/10/2019	4	Recruitment Finished
4	19/YH/0067	254066	CANOPY-1	Number Agreed	3	3	Date Agreed	21/10/2022	0	05/12/2019	0	Recruitment Finished
5	19/NW/0482	269475	Kepler	Number Agreed	2	2	Date Agreed	30/03/2020	2	19/12/2019	2	Recruitment Finished
6	18/EE/0378	248600	Conbercept in Neovascular Age-related Macular Degeneration	Number Agreed	5	5	Date Agreed	31/05/2020	11	18/12/2019	11	Recruitment Finished
7	18/LO/1450	248611	Marigold Study 4407/0001 Marinus	Number Agreed	4	4	Date Agreed	31/12/2019	5	31/12/2019	5	Recruitment Finished
8	17/SW/0174	228278	A Phase 2 Clinical Trial in Patients with AML version amend 4	Number Agreed	1	1	Date Agreed	30/07/2021	1	06/01/2020	1	Recruitment Finished
9	17/LO/1476	224732	A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001	Number Agreed	2	2	Date Agreed	17/01/2020	3	17/01/2020	3	Recruitment Finished
10	16/LO/0814	199311	CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pcJIA) followed by an extension phase	Number Agreed	1	1	Date Agreed	30/06/2020	0	27/01/2020	0	Recruitment Finished
11	16/LO/1960	199019	CHIL4595	Number Agreed	1	1	Date Agreed	30/09/2019	0	27/01/2020	0	Recruitment Finished
12	19/YH/0099	257815	LAT8881 in Neuropathic Pain	Number Agreed	11	11	Date Agreed	31/03/2020	7	31/01/2020	7	Recruitment Finished
13	18/LO/1187	240011	ATHENA - a first line ovarian cancer maintenance trial.	Number Agreed	4	4	Date Agreed	30/04/2020	3	31/01/2020	3	Recruitment Finished
14	19/SC/0113	241916	Idera 2125-MEL-301	Number Agreed	2	2	Date Agreed	31/12/2019	1	05/02/2020	1	Recruitment Finished
15	17/EM/0152	216307	Post-transplant Gilteritinib maintenance in acute myeloid leukaemia	Number Agreed	5	5	Date Agreed	15/02/2020	7	15/02/2020	7	Recruitment Finished
16	19/NI/0110	260538	EluNIR HBR study	Number Agreed	8	8	Date Agreed	31/07/2020	5	28/02/2020	5	Recruitment Finished
17	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	Number Agreed	2	2	Date Agreed	31/03/2020	1	13/03/2020	1	Recruitment Finished
18	16/EE/0446	214004	Niraparib in men with mCRPC and DNA repair anomalies	Number Agreed	2	2	Date Agreed	23/07/2020	3	22/05/2020	5	Recruitment Finished
19	19/YH/0247	266732	4451-STEP TEENS-semaglutide effect in adolescents with obesity	Number Agreed	4	4	Date Agreed	15/07/2020	3	15/07/2020	4	Recruitment Finished
20	19/YH/0158	262107	TRANSITION	Number Agreed	4	4	Date Agreed	31/03/2020	4	20/07/2020	4	Withdrawn By Sponsor
21	17/NE/0238	225047	A Single-dose Pharmacokinetics Study of MK-7655A in Pediatric Subjects	Number Agreed	1	1	Date Agreed	31/08/2020	0	28/07/2020	1	Recruitment Finished
22	19/YH/0013	255993	Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC	Number Agreed	4	4	Date Agreed	30/11/2020	4	19/08/2020	4	Recruitment Finished